BioSpace News Archive

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) today provided unaudited financial results for the quarter ended June 30, 2020.

LKC Technologies is pleased to announce that the Brazilian Health Regulatory Agency (Anvisa) has granted approval of the RETeval® device and LKC Technologies’ Sensor Strips skin electrodes, making this a significant advancement in the preservation and enhancement of sight for patients in Brazil.

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic

CORRECTING and REPLACING Quidel to Present Virtually at the Canaccord Genuity 40 th Annual Growth Conference CORRECTION...Quidel Corporation SAN DIEGO--( BUSINESS WIRE )-- In the first paragraph, the date of the conference should read: Thursday, August 13, 2020 (instead of Wednesday, August 13, 2020). The corrected release reads: QUIDEL TO PRESENT VIRTUALLY AT THE CANACCORD GENUITY 40 th ANNUAL GROWTH CONFERENCE Quidel Corporation (NASDAQ:

Today, the U.S. Food and Drug Administration announced it has issued warning letters to seven companies for illegally selling unapproved products labeled as dietary supplements that claim to cure, treat, mitigate or prevent hangovers, in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The warning letters we

$250,000 top award goes to Lillian Petersen of New Mexico in nation’s oldest and most prestigious STEM competition for high school seniors

Mantra Bio announced it has raised $25 million in a Series A financing to advance development of next generation, precision therapeutics based on its proprietary platform for engineering Targeted Exosome Vehicles.

Deciphera Pharmaceuticals, Inc. announced that it will report its second quarter 2020 financial results on Tuesday, August 4, 2020.

Cutera, Inc., a leading provider of laser and energy-based aesthetic systems for practitioners worldwide, announced that it will report financial results for the second quarter 2020 after the market close on Thursday, August 6, 2020.

INOVIO (NASDAQ: INO) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for INO-3107, its DNA medicine being evaluated in a Phase 1/2 trial for treatment of recurrent respiratory papillomatosis (RRP). RRP is a rare disease caused by human papillomavirus (HPV) types 6 and 11 infec